Clinical relevance of HCV antiviral drug resistance.

Abstract

The approval of direct-acting antiviral agents (DAAs) against the hepatitis C virus (HCV) NS3 protease revolutionized antiviral therapy in chronic hepatitis C. They mark the beginning of an era with drugs designed to inhibit specific viral proteins involved in the virus life cycle rather than the nonspecific antiviral activity of interferon. Upcoming… (More)
DOI: 10.1016/j.coviro.2012.08.008

3 Figures and Tables

Topics

  • Presentations referencing similar topics